DashboardPortfoliosWatchlistCommunityDiscoverScreener
  • Community
  • /
  • Germany
  • /
  • Pharmaceuticals & Biotech
Author Program NEWCreate Narrative
SBX logo

SynBiotic SE Stock Price

XTRA:SBX Community·€6.6m Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 0 Fair Values set on narratives written by author
Author Program NEWCreate Narrative

SBX Share Price Performance

€0
-2.98 (-100.00%)
​
€0
-2.98 (-100.00%)
​
Price €0
Thu, 10 Sep 26
Share Pricen/a

SBX Community Narratives

There are no narratives available yet.
Create Narrative
There are no community narratives available.

Trending Discussion

No trending discussion available.

Recently Updated Narratives

No recently updated narratives available.

Snowflake Analysis

Moderate growth potential with low risk.

3 Risks
1 Reward
View Full Analysis

SynBiotic SE Key Details

€14.9m

Revenue

€9.4m

Cost of Revenue

€5.4m

Gross Profit

€15.1m

Other Expenses

-€9.7m

Earnings

Last Reported Earnings
Dec 31, 2024
Next Reporting Earnings
n/a
0
0%
0%
0%
View Full Analysis

About SBX

Founded
2024
Employees
79
CEO
Daniel Kruse
WebsiteView website
www.synbiotic.com

SynBiotic SE, together with its subsidiaries, engages in the pharmaceutical business in Germany and Europe. It is involved in the cultivation, research, development, production, and distribution of medicinal cannabis; industrial hemp; and cannabidiol and cannabinoid-based products. The company was incorporated in 2024 and is based in Düsseldorf, Germany.

Recent SBX News & Updates

Recent updates

No updates

SynBiotic SE Competitors

PJ2 logo

Liminal BioSciences

Symbol: DB:PJ2
Market cap: €11.8m
0K30 logo

TFF Pharmaceuticals

Symbol: MUN:0K30
Market cap: €9.7m
991 logo

Vitruvia Medical

Symbol: MUN:991
Market cap: €3.0m
View more competitors

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide